TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
April 26 2022 - 7:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael
S. Weiss, the Company’s Chairman and Chief Executive Officer, will
participate in a fireside chat during the B. Riley Securities’ 2022
Virtual Neuro & Ophthalmology Conference, taking place on
Thursday, April 28, 2022, at 12:30 PM ET.
A live webcast of this fireside chat will be available on the
Events page, located within the Investors & Media section, of
the Company’s website at http://ir.tgtherapeutics.com/events. A
replay of the webcast will be available on TG’s website following
the event.ABOUT TG THERAPEUTICSTG
Therapeutics is a biopharmaceutical company focused on the
acquisition, development and commercialization of novel treatments
for B-cell diseases. In addition to a research pipeline including
several investigational medicines, TG has completed a Phase 3
program for ublituximab, an investigational glycoengineered
monoclonal antibody that targets a unique epitope on
CD20-expressing B-cells, to treat patients with relapsing forms of
multiple sclerosis (RMS). For more information,
visit www.tgtherapeutics.com, and follow us on
Twitter @TGTherapeutics and Linkedin.UKONIQ® is
a registered trademark of TG Therapeutics, Inc.CONTACT:
Investor Relations
Email: ir@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option
6
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Apr 2023 to Apr 2024